AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NEURIZON THERAPEUTICS LTD

0.060

+0.0011.69%

Volume:256.24K

Turnover:15.22K

Market Cap:46.51M

PE:-2.03

High:0.060

Open:0.059

Low:0.059

Close:0.059

52wk High:0.165

52wk Low:0.055

Shares:775.10M

Float Shares:351.37M

Volume Ratio:0.41

T/O Rate:0.07%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.030

EPS(LYR):-0.034

ROE:-147.09%

ROA:-60.21%

PB:5.61

PE(LYR):-1.76

Loading ...

Overview Company News Filings

Neurizon Therapeutics Ltd-Elanco Representative Appointed as Neurizon Board Observer

THOMSON REUTERS

Neurizon Therapeutics Draws Down Over AU$8 Million Under R&D Financing Facility

MT Newswires Live

Neurizon Therapeutics Enters Strategic Research and Development Financing Facility

Neurizon Therapeutics - Executes A$17.5 Mln R&D Financing Facility with Dare Capital Loan Fund

THOMSON REUTERS

Healey ALS Platform Trial Regimen I Enrolment Completed - Topline Results for Nuz-001 Accelerated to Q2 Cy2027

THOMSON REUTERS

BUZZ-Australia's Neurizon Therapeutics jumps on deal with US firm

Neurizon Therapeutics Ltd-Neurizon Executes Long-Term Supply Agreement With Elanco

THOMSON REUTERS

Neurizon Therapeutics - to Exclusively Buy Monepantel From Elanco With Specific Alternative Rights

THOMSON REUTERS

Neurizon Therapeutics Surpasses 50% Dosing Milestone in Trial of ALS Treatment

MT Newswires Live

Neurizon to host shareholder webinar on HEALEY ALS trial recruitment expansion

Neurizon expands HEALEY ALS trial Regimen I to 240 participants

Neurizon Therapeutics Receives Ethics Approval For Phase 1 Nuz-001 Oral Liquid Formulation Study

Neurizon Therapeutics Gets Ethics Committee Nod for Neurodegenerative Disease Phase 1 Study; Shares Gain 3%

MT Newswires Live

Neurizon wins ethics approval for NUZ-001 Phase 1 oral liquid study

Neurizon Therapeutics Ltd - Receives Ethics Approval for Phase 1 Nuz-001 Oral Liquid Formulation Study

THOMSON REUTERS

Neurizon appoints Ross Murdoch independent non-executive director

Neurizon Therapeutics Ltd-Neurizon Strengthens Board for the Next Growth Phase

THOMSON REUTERS

Neurizon Therapeutics Ltd-Appendix 4C & Quarterly Update

THOMSON REUTERS

BRIEF-Neurizon Therapeutics Announces Placement Of Entitlement Offer Shortfall To Raise ~A$2.7 Million

Neurizon Therapeutics Ltd - Announces Placement of Entitlement Offer Shortfall to Raise ~a$2.7 Mln

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/NUZ.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NUZ.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","market":"AU","secType":"STK","nameCN":"NEURIZON THERAPEUTICS LTD","latestPrice":0.06,"timestamp":1787292720000,"preClose":0.059,"halted":0,"volume":256243,"delay":0,"changeRate":0.0169491525423729,"nameEN":"NEURIZON THERAPEUTICS LTD","floatShares":351374969,"shares":775099508,"eps":-0.029543,"marketStatus":"Not Yet Opened","change":0.001,"latestTime":"08-21 16:12:00 AEST","open":0.059,"high":0.06,"low":0.059,"amount":15220,"amplitude":0.016949,"askPrice":0.06,"askSize":9409,"bidPrice":0.059,"bidSize":15000,"shortable":3,"etf":0,"ttmEps":-0.029543,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.059,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":0.41067729216162974,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"NUZ.AU","preClose":0.059,"auctionPrice":0.059,"auctionVolume":14773,"auction":3,"marketStatus":"盘后竞价","timestamp":1787292005724}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","floatShares":351374969,"roa":"-60.21%","roe":"-147.09%","lyrEps":-0.034045,"volumeRatio":0.41067729216162974,"shares":775099508,"dividePrice":0,"high":0.06,"amplitude":0.016949,"preClose":0.059,"low":0.059,"week52Low":0.055,"pbRate":"5.61","psRate":"7.78","week52High":0.165,"institutionHeld":0,"latestPrice":0.06,"committee":0.229055,"eps":-0.029543,"divideRate":0,"volume":256243,"delay":0,"ttmEps":-0.029543,"open":0.059,"prevYearClose":0.085,"prevWeekClose":0.062,"prevMonthClose":0.062,"prevQuarterClose":0.06,"fiveDayClose":0.062,"twentyDayClose":0.06,"sixtyDayClose":0.063,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NUZ.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NUZ.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NUZ.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659189541","title":"Neurizon Therapeutics Ltd-Elanco Representative Appointed as Neurizon Board Observer","url":"https://stock-news.laohu8.com/highlight/detail?id=2659189541","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659189541?lang=en_us&edition=fundamental","pubTime":"2026-08-13 07:46","pubTimestamp":1786578416,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUE4DVJX8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658668969","title":"Neurizon Therapeutics Draws Down Over AU$8 Million Under R&D Financing Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2658668969","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658668969?lang=en_us&edition=fundamental","pubTime":"2026-08-11 10:23","pubTimestamp":1786415025,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  completed an initial drawdown of around AU$8.3 million under its research and development (R&D) financing facility with Dare Capital Loan Fund, secured against the company's fiscal 2026 R&D tax incentive rebate, according to a Tuesday filing with the Australian bourse.The funds will primarily support the company's continued investment in the pivotal phase two and phase three Healey ALS platform trial, which is now fully recruited and is expected to deliver results in the late second quarter of fiscal 2027, per the filing.The facility provides up to AU$17.5 million in non-dilutive funding, with annual extension options for fiscal 2027 and fiscal 2028 R&D claims, accruing interest at 1.25% per month and repayable upon receipt of the R&D tax incentive refund, the filing added.The company's shares shed nearly 2% in recent Tuesday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","BK4139","BK4007","BK4539","NUZ.AU","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655337586","title":"Neurizon Therapeutics Enters Strategic Research and Development Financing Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2655337586","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655337586?lang=en_us&edition=fundamental","pubTime":"2026-07-31 14:25","pubTimestamp":1785479159,"startTime":"0","endTime":"0","summary":"BRIEF-Neurizon Therapeutics Enters Strategic Research And Development Financing FacilityJuly 31 -Neurizon Therapeutics LtdNUZ.AX:NEURIZON ENTERS STRATEGIC RESEARCH AND DEVELOPMENT FINANCING FACILITYEXECUTES A$17.5 MILLION RESEARCH AND DEVELOPMENT FINANCING FACILITY WITH DARE CAPITAL LOAN FUNDFurther company coverage:NUZ.AX","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nTUEWBQNF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655892334","title":"Neurizon Therapeutics - Executes A$17.5 Mln R&D Financing Facility with Dare Capital Loan Fund","url":"https://stock-news.laohu8.com/highlight/detail?id=2655892334","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655892334?lang=en_us&edition=fundamental","pubTime":"2026-07-31 13:21","pubTimestamp":1785475287,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nTUEWBQNF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652715994","title":"Healey ALS Platform Trial Regimen I Enrolment Completed - Topline Results for Nuz-001 Accelerated to Q2 Cy2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2652715994","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652715994?lang=en_us&edition=fundamental","pubTime":"2026-07-17 11:49","pubTimestamp":1784260141,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260717:nTUA3HW1PV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644797957","title":"BUZZ-Australia's Neurizon Therapeutics jumps on deal with US firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2644797957","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644797957?lang=en_us&edition=fundamental","pubTime":"2026-06-17 11:38","pubTimestamp":1781667507,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neurizon Therapeutics jumps on deal with US firm** Shares of biotech company Neurizon Therapeutics NUZ.AX jump 12.7% to A$0.071, their highest level since May 18** On track for best d","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nL4N42P08P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1941712264.USD","BK7096","ELAN","NUZ.AU","BK4561","LU1941712348.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644952997","title":"Neurizon Therapeutics Ltd-Neurizon Executes Long-Term Supply Agreement With Elanco","url":"https://stock-news.laohu8.com/highlight/detail?id=2644952997","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644952997?lang=en_us&edition=fundamental","pubTime":"2026-06-17 07:08","pubTimestamp":1781651280,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nTUE5MMMQF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644879521","title":"Neurizon Therapeutics - to Exclusively Buy Monepantel From Elanco With Specific Alternative Rights","url":"https://stock-news.laohu8.com/highlight/detail?id=2644879521","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644879521?lang=en_us&edition=fundamental","pubTime":"2026-06-17 07:08","pubTimestamp":1781651280,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nTUE5MMMQF:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642230058","title":"Neurizon Therapeutics Surpasses 50% Dosing Milestone in Trial of ALS Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2642230058","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642230058?lang=en_us&edition=fundamental","pubTime":"2026-06-12 08:05","pubTimestamp":1781222711,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics (ASX:NUZ) said it dosed over 50% of participants in the first regimen of a trial evaluating NUZ-001 for the treatment of amyotrophic lateral sclerosis, or ALS, according to a Fri","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK7096","NUZ.AU","BK4139","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638890966","title":"Neurizon to host shareholder webinar on HEALEY ALS trial recruitment expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2638890966","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638890966?lang=en_us&edition=fundamental","pubTime":"2026-05-27 22:55","pubTimestamp":1779893714,"startTime":"0","endTime":"0","summary":"Neurizon will host a shareholder webinar on May 28 to discuss the expansion of Regimen I in the HEALEY ALS Platform Trial.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurizon Therapeutics Ltd. published the original content used to generate this news brief on May 27, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL7qRkzs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638952980","title":"Neurizon expands HEALEY ALS trial Regimen I to 240 participants","url":"https://stock-news.laohu8.com/highlight/detail?id=2638952980","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638952980?lang=en_us&edition=fundamental","pubTime":"2026-05-27 07:42","pubTimestamp":1779838967,"startTime":"0","endTime":"0","summary":"Neurizon expanded Regimen I of the HEALEY ALS Platform Trial for NUZ-001 to 240 participants from 160.Topline results were not presented; last patient dosing is projected for Q2 2027, with topline data expected early Q3 2027.Change aims to preserve study power while producing a larger, more consistent dataset to support regulatory and partnering discussions.Cohort now set at 180 treated patients, 60 placebo controls; 113 assigned, 74 dosed as of May 22, 2026.Funding needs through completion are expected to remain unchanged, supported by philanthropic contributions, with only a modest rise in total trial cost.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurizon Therapeutics Ltd. published the original content used to generate this n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL6t9cXY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635122705","title":"Neurizon Therapeutics Receives Ethics Approval For Phase 1 Nuz-001 Oral Liquid Formulation Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2635122705","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635122705?lang=en_us&edition=fundamental","pubTime":"2026-05-13 09:57","pubTimestamp":1778637448,"startTime":"0","endTime":"0","summary":"May 13 (Reuters) - Neurizon Therapeutics Ltd ::*RECEIVES ETHICS APPROVAL FOR PHASE 1 NUZ-001 ORAL LIQUID FORMULATION STUDY*Further company coverage: NUZ.AX* ((Reuters.Briefs@thomsonreuters.com;))  ((R","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nRSD7f2kC3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635222831","title":"Neurizon Therapeutics Gets Ethics Committee Nod for Neurodegenerative Disease Phase 1 Study; Shares Gain 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635222831","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635222831?lang=en_us&edition=fundamental","pubTime":"2026-05-13 08:56","pubTimestamp":1778633814,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  said the Bellberry Human Research Ethics Committee approved its phase 1 study to develop the NUZ-001 oral liquid formulation as a potential treatment for amyotrophic lateral sclerosis , according to a Wednesday filing with the Australian bourse.ALS is a neurodegenerative disorder associated with progressive impairment in speech and swallowing function.The phase 1 trial will enroll 32 healthy volunteers in Australia with the aim of generating safety and other data to guide formulation development and the broader program for NUZ-001, the company said.The study is scheduled to start in the third quarter and be completed in the fourth quarter.Neurizon Therapeutics shares gained 3% in recent Wednesday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NUZ.AU","BK4539","BK7096","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635722921","title":"Neurizon wins ethics approval for NUZ-001 Phase 1 oral liquid study","url":"https://stock-news.laohu8.com/highlight/detail?id=2635722921","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635722921?lang=en_us&edition=fundamental","pubTime":"2026-05-13 07:40","pubTimestamp":1778629242,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics received human research ethics clearance from Bellberry HREC for Phase 1 study of NUZ-001 oral liquid formulation in healthy volunteers.Trial targets start in Q3 2026, completion in Q4 2026.Study will compare oral liquid versus tablet under fed, fasted conditions to support pharmacokinetic, safety, tolerability data for ALS development program.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurizon Therapeutics Ltd. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL4V96BT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635296162","title":"Neurizon Therapeutics Ltd - Receives Ethics Approval for Phase 1 Nuz-001 Oral Liquid Formulation Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2635296162","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635296162?lang=en_us&edition=fundamental","pubTime":"2026-05-13 07:20","pubTimestamp":1778628007,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nFWN41P1IL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634389422","title":"Neurizon appoints Ross Murdoch independent non-executive director","url":"https://stock-news.laohu8.com/highlight/detail?id=2634389422","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634389422?lang=en_us&edition=fundamental","pubTime":"2026-05-11 07:32","pubTimestamp":1778455925,"startTime":"0","endTime":"0","summary":"Neurizon appointed Ross Murdoch as independent non-executive director, effective immediately, as it advances NUZ-001 in the HEALEY ALS Platform Trial.Murdoch brings more than 30 years of pharmaceutical and biotech leadership, including senior roles at AstraZeneca, GlaxoSmithKline, Shire Pharmaceuticals; currently CEO and president of Extractas Bioscience.Michael Thurn retired from board, effective immediately, following previously announced transition from managing director and CEO.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurizon Therapeutics Ltd. published the original content used to generate this news brief on May 10, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260510:nNDLxhXrf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","LU2468319806.SGD","LU0225771236.USD","LU0985481810.HKD","LU1098665638.USD","LU0545562505.USD","SG9999001176.USD","LU1400636657.SGD","IE0034235071.USD","LU0971552673.USD","LU0321505439.SGD","LU1064927863.SGD","NUZ.AU","LU1481599808.USD","IE00B3T34201.USD","SG9999001176.SGD","LU1202635105.USD","LU0557290698.USD","LU0225284248.USD","IE00BQJZX424.USD","LU0058720904.USD","SGXZ57979304.SGD","LU1487256676.USD","LU0203347892.USD","LU0321505868.SGD","LU1015430645.USD","LU1302929846.USD","LU0109981661.USD","LU0225283273.USD","IE00BWDBJ516.SGD","LU1481600234.SGD","GSK.UK","LU1046248800.SGD","LU0161305163.EUR","LU0306806265.USD","LU1228905037.USD","BK7096","LU0575583348.USD","LU0306807586.USD","LU2646069778.SGD","LU0289739699.SGD","LU1983299246.USD","BK5011","LU0987226296.USD","LU0971552830.HKD","LU1035777561.USD","LU1400636574.HKD","SG9999013999.USD","LU0203345920.USD","LU0211331839.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633054691","title":"Neurizon Therapeutics Ltd-Neurizon Strengthens Board for the Next Growth Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2633054691","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633054691?lang=en_us&edition=fundamental","pubTime":"2026-05-08 07:06","pubTimestamp":1778195187,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nTUECH3XD4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631557317","title":"Neurizon Therapeutics Ltd-Appendix 4C & Quarterly Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2631557317","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631557317?lang=en_us&edition=fundamental","pubTime":"2026-04-30 07:38","pubTimestamp":1777505905,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nTUE3FTPKK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627225246","title":"BRIEF-Neurizon Therapeutics Announces Placement Of Entitlement Offer Shortfall To Raise ~A$2.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2627225246","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627225246?lang=en_us&edition=fundamental","pubTime":"2026-04-16 09:42","pubTimestamp":1776303766,"startTime":"0","endTime":"0","summary":"BRIEF-Neurizon Therapeutics Announces Placement Of Entitlement Offer Shortfall To Raise ~A$2.7 MillionApril 16  - Neurizon Therapeutics Ltd NUZ.AX:ANNOUNCES PLACEMENT OF ENTITLEMENT OFFER SHORTFALL TO RAISE ~A$2.7 MILLIONTOTAL AMOUNT TO BE RAISED UNDER ENTITLEMENT OFFER IS ~A$8.5 MILLIONFurther company coverage: NUZ.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nFWN40Y0JF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627147256","title":"Neurizon Therapeutics Ltd - Announces Placement of Entitlement Offer Shortfall to Raise ~a$2.7 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2627147256","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627147256?lang=en_us&edition=fundamental","pubTime":"2026-04-16 07:28","pubTimestamp":1776295709,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nFWN40Y0JF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":32,"code":"91000000","status":"200"}]}}